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The mammalian COP9 signalosome (CSN) complex is involved in cell transformation, but its molec-
ular mechanism remains undetermined. Here we show that disruption of the ﬁfth component
(CSN5) prevented the formation of tumors by p53-null cells transformed with an active form of
Ras in subcutaneously injected mice. Depletion of CSN5 suppressed cell proliferation, and induced
premature senescence characterized by upregulation of senescence-associated-b-galactosidase
activity and increased expression of CDK inhibitors. CSN5-depleted cells exhibited enhanced activa-
tion of the PI3 kinase–Akt pathway, and chemical inhibition of this pathway reduced the level of
senescence. Thus, CSN5 is suggested to be a novel target in cancer therapy and for drugs against
tumor cells harboring mutated p53.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction which removes a ubiquitin-like peptide called NEDD8 from theThe small GTP-binding protein Ras plays a central role in signal
transduction mediated by growth factors and in cell transforma-
tion [1]. Although ectopic expression of constitutively active Ras
in primary cells induces premature senescence and eternal with-
drawal from the cell cycle [2], simultaneous inactivation of the tu-
mor suppressor p53 combined with Ras produces transformed
cells, which form tumors when injected into experimental animals
[3]. Basically, Ras mediates signaling triggered by growth factor
receptors, including a Raf/MEK/ERK pathway (MAPK pathway),
and a PI3 kinase/Akt kinase pathway (PI3K–Akt pathway), both
of which play an essential role in controlling the proliferation, dif-
ferentiation, and survival of mammalian cells [1]. Many factors
have been demonstrated to act downstream of and in parallel with
Ras-mediated oncogenic pathways, among which we focused on
the mammalian COP9 signalosome (CSN) complex [4,5]. The CSN
complex consists of 8 subunits (CSN1–8), and knockdown of the
subunits by siRNA prevented Ras-mediated transformation [6].
However, the precise mechanism remained to be determined.
The CSN complex exhibits multiple functions, which includes
the deneddylase activity [7–9]. The deneddylase is an isopeptidase,chemical Societies. Published by E
of Biological Sciences, Nara
ma, Ikoma, Nara 630-0101,cullin subunit of cullin-RING ubiquitin ligases (CRLs), the largest
family among the ubiquitin ligases, thereby regulating ubiquitina-
tion-dependent proteolysis through the 26S proteasome. The ﬁfth
subunit of the CSN complex (CSN5, also known as Jab1) plays an
important role in deneddylation; the JAMM domain located in
the N-terminus of CSN5 is essential to this function [4,5], presum-
ably serving as a catalytic core of the enzyme. However, the
deneddylation reaction requires the holo–CSN complex. Recently,
bortezomib (Velcade) and thalidomide, chemical inhibitors of the
proteasome and a CRL complex containing cereblon, respectively,
were developed as an anti-cancer drug for multiple myelome
[10–12], indicating that this proteolytic pathway is a novel target
for anti-cancer drugs, and also suggest that the upstream regulator
of this pathway is a potential target for cancer treatment. In fact, an
inhibitor of NEDD8-activating enzyme is a promising anti-cancer
reagent [13]. The CSN complex may also be a good target for
anti-cancer treatment.
We have previously found that in cells originating from Chronic
Myeloid Leukemia (CML), the smaller form of CSN5 was accumu-
lated depending on the activity of Bcr-Abl kinase and knockdown
of CSN5 prevented proliferation of Bcr-Abl-transformed cells [14].
In this signaling, we also found that both PI3 kinase and MAP ki-
nase pathways functioned upstream of the CSN complex. CSN5 is
overexpressed in a variety of human cancers, and its speciﬁc
knockdown prevented proliferation of tumor cells [5]. In animallsevier B.V. All rights reserved.
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ders [15], and knockout of the CSN5 allele resulted in embryonic
lethality at a very early stage [16]. Conditional knockout showed
that CSN5-depletion induced premature senescence in the pres-
ence and absence of p53 [17]. Based on these ﬁndings, we sought
the physiological role of CSN5 in Ras-mediated tumorigenesis
through the inducible knockout of the CSN5 gene in cells trans-
formed using a combination of the nullizygous allele of the p53 tu-
mor suppressor and the ectopic introduction of a constitutively
active form of the Ras oncogene. We found that CSN5-knockout
prevented the formation of tumors by p53-null Ras-transformed
cells in mice by inducing premature senescence. CSN5-depleted
cells were positive for senescence-associated-b-galactosidase
activity, and had increased levels of ARF, and CDK inhibitors p16,
p27, and p21. Interestingly, the PI3-kinase/Akt pathway, but not
the MAP kinase pathway, was enhanced, and treatment with a
PI3 kinase inhibitor, wortmannin, partially prevented senescence.
Thus, CSN5 is an important component for Ras-mediated cell trans-
formation by preventing premature senescence.
2. Materials and methods
2.1. Cell culture, transfection, and retroviral infection
Mouse embryonic ﬁbroblasts (MEFs) harboring null () and
conditional (ﬂoxed, f) alleles of the CSN5/Jab1 gene and immortal-
ized by the null allele of p53 were described previously [16,17].
NIH3T3 (Arf-null, p53-wild-type) mouse ﬁbroblasts (provided by
Drs. C.J. Sherr and M.F. Roussel), MEFs, and 293T human embryonic
kidney (HEK) cells were cultured in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum
(FBS), 2 mM glutamine, 100 units/ml of penicillin, and 100 lg/ml
of streptomycin (GIBCO/BRL). Transfection with expression vectors
was performed by the calcium phosphate–DNA precipitation
method [18]. For viral production, the plasmid was co-transfected
into 293T cells together with a plasmid encoding an ecotropic
helper virus containing a defective virion-packaging (u2) se-
quence. Culture supernatants containing retroviruses were used
to infect mouse ﬁbroblasts [19]. Infected cells were selected for
resistance to puromycin (5 lg/ml) or G418 (1 mg/ml) depending
on the type of vector used for infection and sorted for GFP-positive
signals with a FACS Aria ﬂow cytometer (Becton Dickinson). For the
activation of inducible CRE proteins, MEFs were treated with 4OHT
(200 nM) for 1–4 h. High molecular DNA was extracted from the
cells and genotypes were determined as described [17]. DNA con-
tent and BrdU uptake were measured as described [19,20]. b-
Galactosidase activity was determined as described [17]. In some
experiments, cells were incubated in the presence of wortmannin
(100 nM) and LY294002 (20 lM) before harvest.
2.2. Plasmid construction
The GFP-fused protein expression vectors (pMSCV-puro-GFP
and pMSCV-IRES-GFP, the latter being a gift from Dr. Owen Witte),
into which CRE-ER, ER-CRE-ER (purchased from Addgene Inc.) [21]
and active Ha-Ras (EJ-ras) [22] cDNAs were subcloned, were de-
scribed previously [19]. The vectors for RNA interference (RNAi)
were constructed with the pSUPER RNAI system (pSUPER.retro, pSU-
PER.retro.neo+gfp, and pSUPER.retro.neo, purchased from OligoEn-
gine) according to the manufacturer’s instructions.
2.3. Protein analyses
Cell lysis, sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis (SDS–PAGE), and immunoblotting were performed asdescribed [19,23]. Rabbit polyclonal antibodies to CSN5, Cul1 and
4, p21, GFP, and Skp2 were generated using bacterially produced
polypeptides in our laboratory. Rabbit polyclonal antibodies to
Skp2 (H-435), p27 (C-19), p16 (M156), Erk1 (C-16), Erk2 (C-14),
and ppRb (S780) were obtained from Santa Cruz. Mouse monoclo-
nal antibodies to c-tubulin (GTU88) and Rb (G3-245) were
purchased from Sigma and Pharmingen, respectively. Rabbit poly-
clonal antibodies to Akt (C67E7), phosphorylated Akt (C31E5E and
D9E), and phosphorylated Akt-substrates (100B7E and #9611)
were acquired from Cell Signaling Technology. Mouse monoclonal
antibody to phosphorylated Erk1/2 (pT202/pY204, 20A) and rabbit
polyclonal antibody to p19ARF (ab80) were from BD Transduction
Lab and Abcam, respectively.
2.4. Tumorigenicity assay
Cells (ca 106) were subcutaneously injected into 6-week-old
NOD-SCID mice. Tumors were formed after 8 days. Mice were sac-
riﬁced and the size of the tumor was measured after 10 days post-
injection.
3. Results
3.1. Inducible, conditional knockout of CSN5 in Ras-transformed p53-
null cells
To examine the role of CSN5 in Ras-transformed cells, we con-
ditionally knocked out the CSN5 gene. Because it is difﬁcult to
maintain CSN5-knockout cells for a long period, we utilized an
inducible system in cultured cells to synchronously deplete the
CSN5 protein. Mouse embryonic ﬁbroblasts (MEFs) containing
the ﬂoxed allele of the CSN5 gene and immortalized by the null al-
lele of p53 (CSN5f/-p53/MEFs) [17] were infected with a retrovi-
ral vector encoding a constitutively active Ras and a vector
containing inducible CRE recombinase, which was fused with the
estrogen receptor (ER) gene (CRE-ER) [21]. After selection in puro-
mycin and by cell sorting for GFP-positive signals, 4-Hydroxytam-
oxifen (4OHT) was added to the medium to inactivate the CSN5
locus. Fig. 1A shows that addition of 4OHT efﬁciently converted
the ﬂoxed allele to the deleted form. Incubation of cells with
4OHT for 1–3 h was sufﬁcient to convert all the detectable amount
of ﬂoxed allele into the deleted allele, but it took a little longer for
the CSN5 protein to disappear, and after 3 days, the protein was
undetectable (Fig. 1B). After 7 days, a trace amount of the protein
reappeared. This was due to the proliferation of cells that failed
to convert the ﬂoxed allele of the CSN5 gene.
3.2. Depletion of CSN5 prevented tumor formation in mice
To conﬁrm that the CSN activity is required for Ras-transformed
cells to form tumors in vivo, we subcutaneously injected the cells
prepared as in Fig. 1A and B (CSN5f/-p53/Ras+CRE-ER MEFs) with
and without incubation in 4OHT into NOD-SCID mice (Fig. 1C and
D). Tumors were formed after 8 days, and mice were sacriﬁced and
the size of the tumors was measured after 10 days post-injection.
In contrast to the control (4OHT), deprivation of the CSN5 protein
induced by treatment with 4OHT (+4OHT) markedly reduced the
size of the tumors (Fig. 1C and D). A trace amount of cells remained
in mice at 10 days post-injection but usually failed to proliferate
thereafter. In rare cases, we observed cell proliferation after
14 days post-injection, but genotyping revealed that such cells
retained non-converted ﬂoxed alleles, presumably due to a
non-functioning CRE recombinase. Thus, these results conﬁrmed
that CSN5 is required for Ras-transformed cells to form tumors in
mice.
Fig. 1. Inducible knockout of the CSN5 gene prevented tumor formation in mice. (A)
Mouse embryonic ﬁbroblasts (MEFs) harboring the conditional ﬂoxed locus of CSN5
and the null locus of p53 and introduced with a constitutively active Ras and an
inducible CRE (CRE-ER) (CSN5f/-p53/Ras+CRE-ER MEFs) were incubated with and
without 4OHT for 3 h. High molecular weight DNA was extracted from cells, and the
genotypes were determined by genomic PCR as described [17]. (B) MEFs were
prepared as in A, except that a control (GFP) virus was also used in lieu of active Ras
as a control. Cells were incubated in 4OHT, and harvested 0, 3, 5, and 7 days after
treatment. Cell lysates were analyzed by immunoblotting with antibodies against
CSN5 and c-tubulin. (C) CSN5f/-p53/Ras+CRE-ER MEFs were cultured with and
without 4OHT and subcutaneously injected into NOD-SCID mice (ca 106 cells). At
10 days post-injection, mice were sacriﬁced and the weights of the tumors were
measured. The sites of injection are shown by arrows, and photos of actual tumors
removed from mice are also shown. (D) The summary of 4 independent
experiments of panel C is shown. The data are averages and standard deviations.
P < 0.001.
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premature senescence of p53/ cells containing active Ras
To investigate how depletion of CSN5 prevented tumor forma-
tion, we analyzed their proliferation potential in vitro.
CSN5f/-p53/Ras+CRE-ER and control (infected with a control
GFP virus in lieu of Ras virus) MEFs were incubated with and with-
out 4OHT, plated at low cell density, and enumerated every day for
6–10 days. Fig. 2A shows that depletion of CSN5 markedly sup-
pressed cell proliferation in the presence and absence of active
Ras. Because Ras-transformed cells proliferated to some extent
for a week whereas control cells ceased to proliferate in 2–3 days,
we replated the 4OHT-treated Ras-transformed cells at Day 4, and
enumerated them for a week (Fig. 2B), conﬁrming that the cells
ceased to proliferate in the end. In addition, we cultured Ras-trans-
formed and control cells at Day 5 and 7 after treatment with 4OHT
in the presence of BrdU and enumerated BrdU-positive cells
(Fig. 2C). We found that CSN5-depletion inhibited the incorpora-
tion of BrdU in both Ras-transformed and control cells but Ras-
transformed cells were slightly more resistant, consistent with
the growth curve (Fig. 2A and B). During this period of culture,
we did not observe any signiﬁcant increase in the death and
detachment of cells, suggesting that suppression of cell prolifera-
tion is due not to an increase in cell death or loss from ﬂoatation,
but the blocking of cell proliferation. Flow-cytometric analysis of
DNA content showed little difference in distribution among the
G0/G1, S, and G2/M phases before and after 4OHT treatment
(Fig. 2D), suggesting that the cell cycle was blocked at multiple
points [17].
Under the microscope, 4OHT-treated cells appeared ﬂatter
(Fig. 2E, upper panels), a typical feature of senescent cells. We,
therefore, assayed for senescence-associated (SA) b-galactosidase
(Gal) activity, another marker of premature senescence. Fig. 2E,lower panels show that 4OHT-treated CSN5f/-p53/Ras+CRE-ER
MEFs were positive for SA-b-Gal activity. Thus, we concluded that
depletion of CSN5 induced premature senescence in Ras-trans-
formed cells to prevent tumorigenesis.
3.4. CSN5-depletion upregulated the expression of several senescence-
associated marker molecules and sustained Akt signaling
To examine the changes in signaling molecules caused by CSN5-
depletion, we analyzed the expression of a series of signaling mol-
ecules. CSN5f/-p53/Ras+CRE-ER MEFs were cultured with and
without 4OHT, incubated without 4OHT for 7 days, and harvested.
The expression of each signaling molecule was determined by
immunoblotting (Fig. 3). 4OHT-treatment did not signiﬁcantly
change the level of ectopic Ras expression, and, consistent with
the loss of CSN5 expression, neddylated cullins were accumulated
(Fig. 3A, ﬁrst 4 lanes from the top). As cells underwent senescence,
the expression of the CDK inhibitors p21, p27, and p16 was upreg-
ulated and hypo-phosphorylated Rb protein was accumulated,
whereas the level of Skp2 was maintained (Fig. 3A, lanes 5–10 from
the top). Interestingly, the level of p21 was slightly raised in these
p53-null cells, probably due to the massive inactivation of cullin-
containing ubiquitin ligases.
Because we previously showed that MAP kinase and PI3 kinase
pathways are involved in regulation of the CSN complex depending
on the activity of Bcr-Abl kinase [14], we examined the activation
of these pathways in CSN5-depleted Ras-transformed cells by look-
ing at ERK and Akt kinases. Fig. 3B shows that, although the total
expression levels of ERK1, ERK2, and Akt were maintained, their
activating phosphorylation was modulated by knockout of the
CSN5 gene. The active form of ERK1 and 2 was reduced, whereas
the activating phosphorylation of Akt (serine 473 and threonine
308) was increased after treatment with 4OHT. Furthermore, the
phosphorylation of certain substrates of Akt was enhanced in cells
deprived of CSN5 (Fig. 3C), demonstrating that substrates of Akt as
well as Akt kinase itself were phosphorylated to a great extent in
these cells.
3.5. Inhibition of the PI3 kinase–Akt pathway partially prevented
premature senescence in CSN5-depleted cells
As activation of the PI3 kinase–Akt pathway was reported to in-
duce senescence [24], we investigated the potential role of the in-
creased activity of this pathway in CSN5-depleted Ras-transformed
cells using a chemical inhibitor speciﬁc to PI3 kinase, wortmannin.
CSN5f/-p53/Ras+CRE-ER MEFs were treated with 4OHT, incu-
bated without 4OHT for 7 days, and harvested. Wortmannin was
added to the medium for the last 48 h before harvest. Analysis of
the cell lysate by immunoblotting (Fig. 4A) showed that the acti-
vating phosphorylation of Akt at serine 473 and threonine 308
was enhanced by deprivation of CSN5 but suppressed in the pres-
ence of wortmannin (Fig. 4A, fouth and ﬁfth lanes from the top).
Under these conditions, levels of p27, p16, ARF and p21 were in-
creased by treatment with 4OHT but not signiﬁcantly affected by
wortmannin (Fig. 4A, sixth to ninth lanes from the top). The
amount of Skp2 was affected by neither 4OHT nor wortmannin
(Fig. 4A, tenth lane from the top). In terms of morphology and
SA-b-Gal activity (Fig. 4B), cells became ﬂat and positive for SA-
b-Gal activity following the treatment with 4OHT, but these phe-
notypes were markedly weakened in the presence of wortmannin.
However, the presence of wortmannin did not allow cells to prolif-
erate after treatment with 4OHT. We observed the same pheno-
type when we used a chemical inhibitor more speciﬁc to PI3
kinase, LY294002. Thus, these results show that upregulation of
Akt (or PI3 kinase) activity played an important role in the induc-
tion of premature senescence induced by depletion of CSN5.
Fig. 2. Depletion of CSN5 prevented proliferation and induced premature senescence of cells containing active Ras and nullizygous p53. (A) CSN5f/-p53/Ras+CRE-ER MEFs
and control MEFs were incubated with and without 4OHT, replated at low cell density (2.5  104 cells per plate) and enumerated every day for 6 days. (B) CSN5f/-p53/
Ras+CRE-ER MEFs treated with 4OHT in panel A were replated at Day 4 and enumerated for another 6 days. (C) CSN5f/-p53/Ras+CRE-ER (GFP-Ras) and control (CSN5f/-p53/
GFP+CRE-ER , GFP) MEFs were incubated with and without 4OHT, and replated at low cell density on cover slips. At Day 0, 5, and 7, cells were pulse-labeled with BrdU and
stained with antibody to BrdU. Cells with positive signals for BrdU incorporation were enumerated. (D) CSN5f/-p53/Ras+CRE-ER MEFs were incubated with and without
4OHT. After 7 days, DNA content was analyzed by ﬂow cytometry. (E) CSN5f/-p53/Ras+CRE-ER MEFs cultured with and without 4OHT and then incubated in normal medium
for 7 days were observed under the microscope (phase contrast, PC), and stained for senescence-associated b-galactosidase activity (b-Gal). The data in A–C are averages and
standard deviations for three independent experiments.
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Senescence has been recently recognized as part of the mecha-
nism to prevent tumor development by suppressing and eventu-
ally removing transformed cells from the system [25]. In general,
induction of senescence depends on the activity of the tumor sup-
pressor p53 and its downstream targets such as the CDK inhibitor
p21, and, actually, p53-null cells escape from replicative senes-
cence and proliferate indeﬁnitely [25,26]. However, recent re-
search identiﬁed novel pathways, by which cells undergo
senescence in a p53-independent manner. ARF induced p53-inde-
pendent senescence in melanoma cells [27]. p16INK4a plays a crit-
ical role in p53-independent telomere-directed senescence [28].
Skp2 knockout induced Arf/p53 independent cellular senescence
in PTEN-deﬁcient tumor cells [29]. In this process, upregulation
of CDK inhibitors p27 and p21 caused by Skp2-loss is thought to
play an important role. Cdk4-loss induces Arf/p53-independent
senescence to prevent oncogenic transformation [30]. Although
the precise molecular mechanism acting to control p53-indepen-dent senescence remains to be determined, the ﬁnding that inacti-
vation of Rb causes senescent cells to enter the cell cycle [31]
suggests that the Rb protein plays an essential role in the initiation
and maintenance of senescence as well as in progression through
the G0/G1 phase, and p53 acts upstream of Rb through p21.
In the present study, we showed that depletion of CSN5 induced
senescence in p53-null cells transformed by active Ras. We found
that a hypo-phosphorylated Rb protein was accumulated in
CSN5-depeleted cells (Fig. 5), consistent with the notion that
dephosphorylation of Rb is involved in senescence. We also found
that the activity of Akt was enhanced in CSN5-depleted cells and
chemical inhibition of PI3 kinase by wortmannin reduced activat-
ing phosphorylation of Akt and suppressed premature senescence,
suggesting that deregulated Akt acts on a novel target ultimately
leading to induction of hypo-phosphorylation of Rb to initiate pre-
mature senescence.
Although Akt does induce senescence [24], it occurs through
TORC1 and p53, and is presumably different from the p53-inde-
pendent senescence induced by CSN5-depletion. CSN5-depletion
Fig. 3. Upregulation of senescence-associated CDK inhibitors and enhancement of Akt signaling in CSN5-depleted cells. Lysates from CSN5f/-p53/Ras+CRE-ER MEFs cultured
with and without 4OHT and then incubated in normal medium for 7 days were analyzed by immunoblotting with antibodies against GFP, CSN5, Cul1, Cul4, p21, p27, p16,
pRb, phosphorylated Rb (S780), Skp2, c-tubulin (A), ERK1, ERK2, phosphorylated ERK1/2, Akt, phosphorylated AKT (S473 and T308) (B), and phosphorylated Akt substrates
(100B7E and #9611 for left and right panels, respectively) (C).
Fig. 4. Inhibition of the PI3 kinase–Akt pathway by wortmannin partially rescued CSN5-depleted cells from premature senescence. (A) CSN5f/-p53/Ras+CRE-ER MEFs
cultured with and without 4OHT were incubated in medium in the presence and absence of wortmannin. Cells were harvested and cell lysates were analyzed by
immunoblotting with antibodies against CSN5, GFP, Akt, phosphorylated AKT (T473 and S308), p27, p16, ARF, p21, Skp2, and c-tubulin. (B) MEFs prepared as in panel A were
observed under the microscope (PC), and stained for senescence-associated b-galactosidase activity (b-Gal). Cells with positive signals for b-Gal are marked with arrows. The
result of cells treated with LY294002 is also shown.
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however, treatment with wortmannin reduced the level of senes-
cence without altering the expression of p16, p21, p27, and ARF,
suggesting that depletion of CSN5 triggers premature senescence
via a novel mediator under the control of Akt.
In addition, it is known that arresting cells in G0/G1 is not suf-
ﬁcient to induce senescence and additional signal is required to
push cells from G0/G1 arrest into the senescent state. The system
used in this study may be ideal for investigating this unknown sig-
naling pathway that executes the ﬁnal step in the induction ofsenescence. Whatever the mechanism, it is feasible that a CSN5-
associated function is required for the Ras-mediated transforma-
tion of cells to prevent premature senescence and, therefore,
CSN5 is a novel target for development of drugs effective against
cancer cells that harbor mutations in the p53 allele to prevent pro-
liferation. However, total depletion of CSN5 results in a destruction
of the holo–CSN complex, leading to pleiotropic defects on cell
function including cell cycle arrest at multiple points, which will
probably cause severe side effects. Therefore, it would be prefera-
ble to pinpoint the signaling pathway speciﬁcally associated with
Fig. 5. A model of the control of senescence mediated by CSN5 in the Ras-mediated
signaling pathway.
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of CSN5, and manipulation of that speciﬁc factor or pathway will
be a solution to the development of desirable drugs.
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